Latest News From Lumira Ventures

Aurinia Partners with National Kidney Foundation on Awareness Initiative

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced new initiatives to support the lupus nephritis (LN) community …

Aurinia Appoints New Chief Commercial Officer & Expands U.S. Leadership

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Max Colao to the newly created position of Chief Commercial …

Aurinia Closes $191.7M Public Offering of Common Shares

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, …

Aurinia Prices US$166.7M Public Offering of Common Shares

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165 common shares (the “Offering”). …

Aurinia Demonstrates Voclosporin’s Superiority over Standard-of-Care in Lupus Nephritis

Jennifer Schram Aurinia Pharmaceuticals, Main Page, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced positive efficacy and safety results from its pivotal …

Aurinia Completes Last Patient Study Visit in AURORA Phase 3 Lupus Nephritis Study & Provides Update on ATM Facility

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today reported that the last patient study visit has …

Aurinia Releases Q2 2019 Financial Results

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

Related Article: Aurinia Reports First Quarter 2019 Financial Results & Recent Operational Highlights Review condensed consolidated financials here: https://ir.auriniapharma.com/press-releases/detail/153 VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused …